{"id":591012,"date":"2022-03-14T13:26:01","date_gmt":"2022-03-14T13:26:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=591012"},"modified":"2022-03-14T13:26:01","modified_gmt":"2022-03-14T13:26:01","slug":"amyotrophic-lateral-sclerosis-pipeline-drugs-key-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/amyotrophic-lateral-sclerosis-pipeline-drugs-key-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments_591012.html","title":{"rendered":"Amyotrophic Lateral Sclerosis Pipeline Drugs & Key Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments"},"content":{"rendered":"
\n
\"Amyotrophic<\/a><\/div>\n
\n
Amyotrophic Lateral Sclerosis (ALS) pipeline insights<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s, \u201cAmyotrophic Lateral Sclerosis (ALS) \u2013 Pipeline Insight, 2022,\u201d report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Amyotrophic Lateral Sclerosis (ALS) pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/div>\n

DelveInsight’s “Amyotrophic Lateral Sclerosis Pipeline Insight”<\/a><\/strong> report provides comprehensive insights about key companies and pipeline drugs in the Amyotrophic Lateral Sclerosis pipeline landscapes. <\/p>\n

The report comprises Amyotrophic Lateral Sclerosis pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Amyotrophic Lateral Sclerosis therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Amyotrophic Lateral Sclerosis pipeline products.     <\/p>\n

Amyotrophic Lateral Sclerosis Overview<\/strong><\/p>\n

Amyotrophic Lateral Sclerosis (ALS), commonly known as Lou Gehrig’s disease, is a group of rare neurological diseases that mainly involve the nerve cells (neurons), responsible for controlling voluntary muscle movement. Voluntary muscles produce movements like chewing, walking, and talking. The disease is progressive, meaning the symptoms get worse over time. ALS belongs to a broader group of disorders known as motor neuron diseases, which are caused by gradual deterioration and death of motor neurons. Motor neurons are nerve cells that extend from the brain to the spinal cord and to muscles throughout the body. <\/p>\n

Some of the key takeaways from the Amyotrophic Lateral Sclerosis Pipeline Report:<\/a><\/strong><\/p>\n